DREW DYKES: Open Payments
NPI 1033779087 · BATON ROUGE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,639 in 142 payments from 13 companies in 2025. Trend: 2023 $3,306 · 2024 $2,646 · 2025 $2,639
Food & beverage: $2,527Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 24 | $499 |
| Alkermes, Inc. | 23 | $381 |
| Otsuka America Pharmaceutical, Inc. | 17 | $283 |
| Vanda Pharmaceuticals Inc. | 13 | $244 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $237 |
| E.R. Squibb & Sons, L.L.C. | 11 | $206 |
| Neurocrine BioSciences, Inc. | 7 | $184 |
| Axsome Therapeutics, Inc. | 7 | $171 |
| Janssen Pharmaceuticals, Inc | 7 | $167 |
| ABBVIE INC. | 11 | $162 |
Products named: ARISTADA, UZEDY, REXULTI, FANAPT, CAPLYTA, COBENFY, INGREZZA, Auvelity.
Industry payments across LA — which companies pay providers there.
